Clinical Research Directory

Inclusion Criteria: * Patient age≥18 years; * No gender preference; * Diagnosed with acute ischemic stroke; * From onset to treatment ≤48 h; * 6≤ NIHSS scores ≤25; * Premorbid mRS ≤1; * Signed informed consent. Exclusion Criteria: * Baseline HAMD-24 scores ≥8; * Infarction area overlapped with the area where the DTI-ALPS index is calculated; * A history of severe mental illness such as depression, bipolar disorder, and schizophrenia; * A history of mental disorders caused by other organic diseases, such as post-Parkinson depression; * Participants with cognitive impairment, disturbance of consciousness, severe hearing impairment, or aphasia who were unable to cooperate with the assessment; * A history of autoimmune diseases (such as multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, etc.), malignant tumors, or obstructive sleep apnea hypopnea syndrome; * Intracranial tumor, arteriovenous malformation, or aneurysm; * Uncontrolled severe hypertension (systolic pressure \>180mmHg or diastolic pressure \>110 mmHg after drug treatment) ; * Subclavian artery stenosis≥50% or subclavian steal syndrome; * Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.; * Severe coagulation dysfunction, platelet count \< 100×10\^9/L, cardiac dysfunction (NYHA class Ⅲ or above), hepatic dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times the upper limit of normal), or renal dysfunction (serum creatinine \> 265μmol/L); * Any contraindication for magnetic resonance imaging: metal implants, claustrophobia, etc.; * Women known to be pregnant or lactating, or have a positive pregnancy test; * Participating in other clinical trials within three months; * Participants not suitable for this clinical studies considered by researcher.